Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Gross Profit

Gross Profit at other companies

Eli Lilly logo
Eli LillyLLY
$19.71B+50.3%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$21.29M+0.6%
Delcath Systems logo
Delcath SystemsDCTH
$26.15M+25.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$54.21M+10.8%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$4.3M—
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.88B+57.6%
Enterprise value$11.96B+59.9%
P/S9.3×-5.4×

Profitability

See full
Gross margin96.5%—
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Calculated from Madrigal Pharmaceuticals, Inc.’s reported figures.

$103.3Mtotal revenue−$1.6Mtotal cost of revenue=$43.48M

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-K, filed February 26, 2025. Open the filing →

Filed
Feb 26, 2025
Fiscal year
FY2024
Accession
0001628280-25-007980

FAQ

What is Madrigal Pharmaceuticals, Inc.'s gross profit?
Madrigal Pharmaceuticals, Inc. (MDGL) reported gross profit of $43.48M in Q4 2024.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.

Ask your AI about Madrigal Pharmaceuticals, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude